Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies바이러스 유사 입자는 mRNA 유도 항체를 강화하기 위한 효율적인 도구입니다Article Published on 2022-06-162022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] antibodies Antibody Response Antibody responses approved boost COVID-19 economics Efficacy efficient Heterologous heterologous prime-boost heterologous prime-boost vaccination strategies homologous investigated maintain mRNA mRNA-1273 mRNA-1273 vaccine overcome Particle priming reduced regimen SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant the antibody response Vaccination strategy Vaccine vaccine candidate Virus-like particle virus-like particles VLP VLPs VOCs were used [DOI] 10.3389/fimmu.2022.864718 PMC 바로가기 [Article Type] Article
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations류마티스성 근골격계 질환의 면역억제제 치료는 SARS-CoV-2 감염에 대한 체액 반응의 유발을 억제하지 않고 이펙터 면역 세포 집단을 보존합니다Article Published on 2022-06-102022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 치료법, [키워드] adaptive addition affected Analysis antibody Antibody Response Antibody responses Arthritis B lymphocytes biologic carried Cellular immune response COVID-19 CTLA4 disease disease-modifying anti-rheumatic drug Disease-modifying anti-rheumatic drugs Diseases DMARD drug effector elicit functional humoral Humoral and cellular immune responses immune immune cell populations immune response immune responses immune system immunological Immunosuppressant include individual Inflammatory Inflammatory arthritis inhibitor inhibitors life-threatening Musculoskeletal Neutralizing activity Pathologies Patient patients treated Population presenting provide RBD protein RBD proteins Re-infections response rheumatic musculoskeletal diseases. SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleocapsid sustained the antibody response TNF-α Treatment virus [DOI] 10.3389/fimmu.2022.873195 PMC 바로가기 [Article Type] Article
Differential antibody production by symptomatology in SARS-CoV-2 convalescent individualsSARS-CoV-2 회복기 개인의 증상에 따른 차등 항체 생산Article Published on 2022-06-092022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법, [키워드] 95% CI absence adjusted odds ratio age analyzed antibody antibody levels antibody production Antibody Response Antibody responses association associations Bio-rad characterized convalescent individual convalescent plasma correlated COVID-19 symptom COVID-19 symptoms detectable ELISA exhibiting generate identify IgA IgG IgM individual infected with SARS-CoV-2 information lack Logistic regression nucleocapsid plasma Rapid test rapid test) RBD Receptor binding domain respiratory respiratory symptom robust S1 subunit SARS-CoV-2 SARS-CoV-2 infected individual SARS-CoV-2 infected individuals SARS-COV-2 infection seropositive Severity of infection Sex significantly sore throat Support Symptom tested the antibody response was used without symptom [DOI] 10.1371/journal.pone.0264298 PMC 바로가기 [Article Type] Article
Potent cross-reactive antibodies following Omicron breakthrough in vaccineesArticle Published on 2022-06-092023-07-09 Journal: Cell [Category] COVID19(2023년), [키워드] Antibody responses BA.1 BA.1.1 BA.2 COVID-19 Crystallography Immune escape neutralization omicron Receptor binding domain SARS-CoV-2 variants of concern [DOI] 10.1016/j.cell.2022.05.014 PMC 바로가기
Persistence of immune responses to the Sinopharm/BBIBP-CorV vaccineSinopharm/BBIBP-CorV 백신에 대한 면역 반응의 지속성Article Published on 2022-06-012022-09-11 Journal: Immunity, Inflammation and Disease [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술, [키워드] ACE2 age all age groups angiotensin Angiotensin-converting enzyme antibody Antibody Response Antibody responses assays blocking antibodies Cell Cohort COVID-19 declined detectable determine Efficacy ELISPOT ELISpot assays enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay Ex vivo group groups Hospitalization immune response immune responses Immunity individual individuals interferon gamma investigated Kinetics long term memory B memory B cell overlapping peptide peptides persistence Protein RBD receptor Receptor-binding domain remained response SARS-CoV-2 second dose severe disease Sinopharm Sinopharm/BBIBP-CorV Spike protein T cell T cell response T cell responses the RBD the receptor-binding domain the spike protein the vaccine total antibodies total antibody Vaccine Vaccines variants variants of concern virus were assessed were measured [DOI] 10.1002/iid3.621 PMC 바로가기 [Article Type] Article
Development of flow cytometry-based assays to assess the ability of antibodies to bind to SARS-CoV-2-infected and spike-transfected cells and mediate NK cell degranulationSARS-CoV-2 감염 및 스파이크 형질감염 세포에 결합하고 NK 세포 탈과립을 매개하는 항체의 능력을 평가하기 위한 유세포 분석 기반 분석법 개발Article Published on 2022-06-012022-09-11 Journal: Cytometry. Part A : the journal of the Internation [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료제, [키워드] antibody Antibody binding Antibody Response Antibody responses Antibody titer Antibody titers assays binding capture Cell cells Clinical studies correlation COVID-19 degranulation demonstrated detect determine develop development Dilution dilution sery Efficiency effort elicited facilitate function functional antibody response healthy control high correlation Immunity IMPROVE infected cell infected cell. infected cells infected individuals magnitude moderate NK cell NK cell degranulation outcome overlap pandemic plasma platform ranged reduce response response rates responses SARS-CoV-2 SARS-CoV-2 disease SARS-COV-2 infection SARS-CoV-2 pandemic SARS-CoV-2-infected cell SARS-CoV-2-infected cells SARS-CoV-2-infected individual SARS-CoV-2-infected individuals Spearman the SARS-CoV-2 transfected cells Undetermined vaccination [DOI] 10.1002/cyto.a.24552 PMC 바로가기 [Article Type] Article
SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and OmicronSARS-CoV-2 변종 노출은 Delta 및 Omicron을 포함한 기존 및 신규 균주의 차등 교차 중화를 통해 항체 반응을 이끌어냅니다.Article Published on 2022-06-012022-09-11 Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 antibody antibody escape Antibody Response Antibody responses B.1.1.529 B.1.1.529 (omicron) B.1.617.2 B.1.617.2 (Delta) booster vaccination breadth contribute coronavirus COVID-19 cross-neutralization Delta exposure exposure to immune immune exposure immune response immune responses Including increase individual Infection natural infection neutralization Neutralizing antibody response neutralizing antibody responses omicron phenotype Phenotypes respiratory response SARS-CoV-2 sensitivity sera severe acute respiratory syndrome Coronavirus spike mutation Spike protein spike variant strain Transmission vaccination variant variants variants of concern [DOI] 10.1093/infdis/jiab635 PMC 바로가기 [Article Type] Article
Efficacy of antibody response following the vaccination of SARS-CoV-2 infected and noninfected healthcare workers by two-dose inactive vaccine against COVID-19COVID-19에 대한 2회 접종 불활성 백신에 의한 SARS-CoV-2 감염 및 비감염 의료 종사자의 백신 접종 후 항체 반응의 효능Article Published on 2022-06-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG anti-SARS-CoV-2 IgG antibodies anti-SARS-CoV-2 IgG antibody antibody Antibody Response Antibody responses appearance classical Comorbidities concerning coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection Day demographics detect Efficacy first dose healthcare worker IgG antibodies IgG level IgG levels immunogenicity Immunosuppression inactive individuals infected with SARS-CoV-2 Infection information investigated majority Neutralizing activity positive postvaccination produced rapid increase SARS-CoV-2 screened second dose second vaccination seropositive seropositive individual seropositive individuals Seropositivity significantly higher Sinovac subject subjects Support Symptoms titers vaccination Vaccine virus [DOI] 10.1002/jmv.27649 PMC 바로가기 [Article Type] Article
Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational StudyOcrelizumab 및 기타 질병 수정 요법을 사용하는 다발성 경화증 환자의 SARS-CoV-2 감염에 대한 세포 및 체액 면역: 다민족 관찰 연구Observational Study Published on 2022-06-012022-09-11 Journal: Annals of neurology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료법, [키워드] age ANN antibody Antibody Response Antibody responses assays association Asymptomatic cellular Cellular and humoral immunity Cellular and humoral responses Cellular immune response chemiluminescence immunoassay Clinical course Clinical severity coronavirus disease Coronavirus disease 2019 correlated correlation COVID-19 determine domain Effect ELISA ELISPOT ELISpot assays enzyme-linked immunosorbent enzyme-linked immunosorbent assay evaluated Evidence evidence of group Hospitalized humoral Humoral and cellular immune responses Humoral immunity Humoral response humoral responses IFNγ IL-2 immune responses immunoassay immunologic response immunologic responses Infection Laboratory Live virus microneutralization MOST Multiple multiple sclerosis multivariate analyses Multivariate analysis N-terminal domain Natalizumab not differ Ocrelizumab Other Patient performed Protein RBD receptor recruited respiratory response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike sclerosis Severe acute respiratory syndrome severity Spearman sphingosine spike Spike protein symptomatic infection T-cell Response T-cell responses therapy with COVID-19 [DOI] 10.1002/ana.26346 PMC 바로가기 [Article Type] Observational Study
Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination감염 및 예방 접종 후 이종 SARS-CoV-2-중화 활동Article Published on 2022-05-302022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] activity acute respiratory syndrome acute respiratory syndrome coronavirus addition analyzed antibody Antibody Response Antibody responses best Beta Cohort coronavirus COVID-19 COVID-19 vaccination D614G declined decrease Delta dose exceeded greater heterogeneity Hospitalized hospitalized patient hospitalized patients Humoral immunity Immunity Improvements individual infected individual infected individuals infecting Infection lowest mRNA vaccine Mutation N-terminal domain neutralization neutralization titer neutralizing activities Neutralizing activity Neutralizing antibodies neutralizing antibody responses no difference not differ pandemic Patient patients Protein recognize respiratory SARS-CoV-2 SARS-CoV-2 spike SARS-CoV-2 variant SARS-CoV-2 variants SARS-CoV-2-neutralizing antibodies SARS-CoV-2-specific antibody responses SARS-CoV-2-specific neutralizing antibodies second vaccination sequence serum sample serum samples severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 significantly significantly lower Specific specific neutralizing antibodies Spike protein symptom onset the SARS-CoV-2 the spike protein vaccinated individual vaccinated individuals Vaccine vaccinee vaccinees variants variants of concern viral strain viral strains virus infection VoC VOCs [DOI] 10.3389/fimmu.2022.888794 PMC 바로가기 [Article Type] Article